In pancreatic cancer cells, BiXAbTM targeting ErbB heterodimers inhibited the phosphoproteome and cell proliferation better than homodimer-specific BiXAbTM, unlike dual HER2 targeting of non-overlapping epitopes by BsAbs (39) or 2MAbs (72) in breast cancer. This evidence concerns the gene ERBB2 and breast cancer.